Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

This study has been terminated.
(Primary endpoint not met)
AVEO Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Bassel El-Rayes, Emory University Identifier:
First received: March 6, 2013
Last updated: March 3, 2015
Last verified: March 2015
The purpose of this study is to learn about the effect of the investigational agent tivozanib on the control of the tumor growth in hepatocellular (liver) cancer. The investigators also plan to collect information on the likelihood to develop side effects while on this treatment. Tivozanib is an oral medication (pill) taken once a day. This medication is designed to stop the tumor from developing new blood vessels.

Condition Intervention Phase
Hepatocellular Cancer
Drug: Tivozanib
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

Resource links provided by NLM:

Further study details as provided by Emory University:

Primary Outcome Measures:
  • Number of patients with advanced hepatocellular cancer (HCC) receiving tivozanib who are free the proportion of patients with advanced HCC receiving tivozanib who are free from progression [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
    Evaluation of disease progression will be made using CT or MRI scan of the organ(s) with the target lesion(s).

Secondary Outcome Measures:
  • Response rate based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

    Measurable lesions: Lesions that can be measured in at least one dimension as ≥ 20 mm with conventional CT scan techniques or as ≥ 10 mm with spiral CT scan.

    Non-measurable lesions: All other lesions including small lesions (longest diameter < 20 mm with conventional techniques) and other non-measurable lesions including: pleural effusions, ascites, and disease documented by indirect evidence (e.g. biochemical abnormalities).

    Target lesions: All measurable lesions up to a maximum of 5 lesions. Target lesions are selected for their size and suitability for accurate repetitive measurements. The sum of the longest diameter of all target lesions will be calculated and reported as the baseline sum longest diameter (LD). This will be used as a reference to further quantify objective response.

    Non-target lesions: All other lesions are identified as non-target lesions and should be followed as present or absent.

Enrollment: 7
Study Start Date: March 2013
Study Completion Date: February 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tivozanib
Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.
Drug: Tivozanib
Oral medication given daily. No placebo.
Other Name: AV-951

Detailed Description:

Angiogenesis is the formation of new blood vessels. Angiogenesis is driven by cytokines including vascular endothelial growth factor. Tivozanib is an oral medication that inhibits vascular endothelial growth factor preventing tumor from developing new blood vessels.

The purpose of this study is to evaluate the effects of tivozanib on hepatocellular (liver) cancer. Participants in the study take tivozanib daily at a dose of 1 mg for 1month. if doing well the dose would be increased to 1.5 mg per day. Patients are monitored for response using CT or MRI scans every 2months. In addition, patients will have blood draws to evaluate the effects of tivozanib on blood vessels.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with measurable, histological diagnosis of HCC and whose disease is not amenable to surgical or regional therapy.
  2. Prior allowed therapy:

    • Surgery including hepatic resection

      1. Minimum of 4 weeks since any surgical procedure.
      2. Patients must have adequately recovered from surgery.
    • Regional therapy

      1. Includes transarterial chemoembolization (TACE, DEB-TACE), percutaneous ethanol injection, radiofrequency/cryo ablation, Yttrium-90 radioembolization.
      2. More than 2 weeks must have lapsed from therapy.
      3. There must be an indicator lesion outside the treated area or clear evidence of progression in the treated lesion, not amenable for further local therapies.
      4. Concomitant sorafenib with regional therapy is allowed as long as no evidence of progression on sorafenib.
    • Prior adjuvant sorafenib is allowed, if completed more than 6 months prior to disease recurrence.
  3. Adequate hematological, liver and metabolic organ function.
  4. Signed informed consent.

Exclusion Criteria:

  1. Patients with mixed histology or fibrolamellar variant.
  2. Prior systemic therapy for metastatic disease.
  3. Uncontrolled hypertension (HTN).
  4. Symptomatic heart failure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01807156

United States, Georgia
Emory University, Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
AVEO Pharmaceuticals, Inc.
Principal Investigator: Bassel El-Rayes, MD Emory University Winship Cancer Institute
  More Information

No publications provided

Responsible Party: Bassel El-Rayes, Study Principal Investigator, Emory University Identifier: NCT01807156     History of Changes
Other Study ID Numbers: IRB00061422  IRB00061422  WINSHIP2302-12 
Study First Received: March 6, 2013
Last Updated: March 3, 2015
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Emory University:
Advanced hepatocellular cancer

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms by Site processed this record on February 07, 2016